1. Siva Kolluri
  2. Siva Kolluri

Primary tabs

Siva Kolluri

Found 40 results
Author [ Title(Desc)] Type Year
Filters: Author is Siva Kolluri
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
I
M. C. Pearce, Gamble, J. T., Kopparapu, P. R., O'Donnell, E. F., Mueller, M. J., Jang, H. Sang, Greenwood, J. A., Satterthwait, A. C., Tanguay, R. L., Zhang, X. -kun, and Kolluri, S., “Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells.”, Oncotarget, vol. 9, no. 40, pp. 26072-26085, 2018.
T
A. K. Ehrlich, Pennington, J. M., Bisson, W. H., Kolluri, S., and Kerkvliet, N. I., “TCDD, FICZ, and other high affinity AhR ligands dose-dependently determine the fate of CD4+ T cell differentiation.”, Toxicol Sci, 2018.
A
A. K. Ehrlich, Pennington, J. M., Tilton, S., Wang, X., Marshall, N. B., Rohlman, D., Funatake, C., Punj, S., O'Donnell, E. F., Yu, Z., Kolluri, S., and Kerkvliet, N. I., “AhR activation increases IL-2 production by alloreactive CD4 T cells initiating the differentiation of mucosal-homing Tim3 Lag3 Tr1 cells.”, Eur J Immunol, vol. 47, no. 11, pp. 1989-2001, 2017.
E. F. O'Donnell, Jang, H. Sang, Pearce, M. C., Kerkvliet, N. I., and Kolluri, S., “The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth inhibition by SU5416 in hepatoma cells.”, Oncotarget, vol. 8, no. 15, pp. 25211-25225, 2017.
I
H. Sang Jang, Pearce, M. C., O'Donnell, E. F., Nguyen, B. Duc, Truong, L., Mueller, M. J., Bisson, W. H., Kerkvliet, N. I., Tanguay, R. L., and Kolluri, S., “Identification of a Raloxifene Analog That Promotes AhR-Mediated Apoptosis in Cancer Cells.”, Biology (Basel), vol. 6, no. 4, 2017.
H. Jang, Pearce, M. C., O'Donnell, E. F., Nguyen, B., Truong, L., Mueller, M. J., Bisson, W. H., Kerkvliet, N. I., Tanguay, R. L., and Kolluri, S., “Identification of a Raloxifene Analog That Promotes AhR-Mediated Apoptosis in Cancer Cells”, Biology (Basel), vol. 6, no. 4, 2017.
R
S. Kolluri, Jin, U. - H., and Safe, S., “Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target.”, Arch Toxicol, vol. 91, no. 7, pp. 2497-2513, 2017.
A
A. K. Ehrlich, Pennington, J. M., Wang, X., Rohlman, D., Punj, S., Löhr, C. V., Newman, M. T., Kolluri, S., and Kerkvliet, N. I., “Activation of the Aryl Hydrocarbon Receptor by 10-Cl-BBQ Prevents Insulitis and Effector T Cell Development Independently of Foxp3+ Regulatory T Cells in Nonobese Diabetic Mice.”, J Immunol, vol. 196, no. 1, pp. 264-73, 2016.
D. C. Koch, Jang, H. S., O'Donnell, E. F., Punj, S., Kopparapu, P. R., Bisson, W. H., Kerkvliet, N. I., and Kolluri, S., “Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1.”, Oncogene, 2015.
E. F. O'Donnell, Koch, D. C., Bisson, W. H., Jang, H. S., and Kolluri, S., “The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells”, Cell death & disease, vol. 5, p. e1038, 2014.
B
S. Punj, Kopparapu, P., Jang, H. Sang, Phillips, J. Lynne, Pennington, J. M., Rohlman, D., O'Donnell, E. F., Iversen, P. L., Kolluri, S., and Kerkvliet, N. I., “Benzimidazoisoquinolines: a new class of rapidly metabolized aryl hydrocarbon receptor (AhR) ligands that induce AhR-dependent Tregs and prevent murine graft-versus-host disease.”, PLoS One, vol. 9, no. 2, p. e88726, 2014.
M
C. V. Gerlach, Das, S. R., Volz, D. C., Bisson, W. H., Kolluri, S., and Tanguay, R. L., “Mono-substituted isopropylated triaryl phosphate, a major component of Firemaster 550, is an AHR agonist that exhibits AHR-independent cardiotoxicity in zebrafish”, Aquatic Toxicology, vol. 154, pp. 71 - 79, 2014.
C. V. Gerlach, Das, S. R., Volz, D. C., Bisson, W. H., Kolluri, S., and Tanguay, R., “Mono-substituted isopropylated triaryl phosphate, a major component of Firemaster 550, is an AHR agonist that exhibits AHR-independent cardiotoxicity in zebrafish”, Aquatic Toxicology, vol. 154, pp. 71–79, 2014.
S
A. Perkins, Phillips, J. Lynne, Kerkvliet, N. I., Tanguay, R., Perdew, G. H., Kolluri, S., and Bisson, W. H., “A structural switch between agonist and antagonist bound conformations for a ligand-optimized model of the human aryl hydrocarbon receptor ligand binding domain”, Biology, vol. 3, pp. 645–669, 2014.
A. Perkins, Phillips, J. Lynne, Kerkvliet, N., Tanguay, R., Perdew, G., Kolluri, S., and Bisson, W. H., “A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain”, Biology, vol. 399, no. 4, pp. 645 - 669, 2014.
A
S. Sengupta, Bisson, W. H., Mathew, L. K., Kolluri, S., and Tanguay, R. L., “Alternate glucocorticoid receptor ligand binding structures influence outcomes in an in vivo tissue regeneration model”, Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, vol. 156, no. 2, pp. 121 - 129, 2012.
E. F. ’ Donnell, Kopparapu, P. Rao, Koch, D. C., Jang, H. Sang, Phillips, J. Lynne, Tanguay, R. L., Kerkvliet, N. I., and Kolluri, S., “The Aryl Hydrocarbon Receptor Mediates Leflunomide-Induced Growth Inhibition of Melanoma Cells”, PLoS ONE, vol. 7, no. 7, p. e40926, 2012.
I
K. J. Smith, Murray, I. A., Tanos, R., Tellew, J., Boitano, A. E., Bisson, W. H., Kolluri, S., Cooke, M. P., and Perdew, G. H., “Identification of a high-affinity ligand that exhibits complete aryl hydrocarbon receptor antagonism”, Journal of Pharmacology and Experimental Therapeutics, vol. 338, pp. 318–327, 2011.
S
I. A. Murray, Flaveny, C. A., Chiaro, C. R., Sharma, A. K., Tanos, R. S., Schroeder, J. C., Amin, S. G., Bisson, W. H., Kolluri, S., and Perdew, G. H., “Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3′, 4′-dimethoxy-$\alpha$-naphthoflavone”, Molecular pharmacology, vol. 79, pp. 508–519, 2011.
A
E. F. O'Donnell, Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R. L., and Kolluri, S., “The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor”, PLoS ONE, vol. 5, no. 10, p. e13128, 2010.
E
A. D. Benninghoff, Bisson, W. H., Koch, D. C., Ehresman, D. J., Kolluri, S., and Williams, D. E., “Estrogen-like activity of perfluoroalkyl acids in vivo and interaction with human and rainbow trout estrogen receptors in vitro”, Toxicological sciences, p. kfq379, 2010.
M
W. H. Bisson, Koch, D. C., Donnell, E. F. ’, Khalil, S. M., Kerkvliet, N. I., Tanguay, R. L., Abagyan, R., and Kolluri, S., “Modeling of the Aryl Hydrocarbon Receptor (AhR) Ligand Binding Domain and Its Utility in Virtual Ligand Screening to Predict New AhR Ligands”, Journal of Medicinal Chemistry, vol. 52, no. 18, pp. 5635 - 5641, 2009.
S
S. Kolluri, Zhu, X., Zhou, X., Lin, B., Chen, Y., Sun, K., Tian, X., Town, J., Cao, X., Lin, F., Zhai, D., Kitada, S., Luciano, F., O'Donnell, E. F., Cao, Y., He, F., Lin, J., Reed, J. C., Satterthwait, A. C., and Zhang, X. -kun, “A Short Nur77-Derived Peptide Converts Bcl-2 from a Protector to a Killer”, Cancer Cell, vol. 14, no. 4, pp. 285 - 298, 2008.
N
F. Luciano, Krajewska, M., Ortiz-Rubio, P., Krajewski, S., Zhai, D., Faustin, B., Bruey, J. - M., Bailly-Maitre, B., Lichtenstein, A., Kolluri, S., Satterthwait, A. C., Zhang, X. - K., and Reed, J. C., “Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma”, Blood, vol. 109, no. 9, pp. 3849 - 3855, 2007.
R
Y. H. Han, Cao, X., Lin, B., Lin, F., Kolluri, S., Stebbins, J., Reed, J. C., Dawson, M. I., and Zhang, X. K., “Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt”, Oncogene, vol. 25, pp. 2974–2986, 2006.